The JAK-STAT signaling pathway plays a central role in signal transduction in hematopoietic
cells, as well as in cells of the immune system. The occurrence in most patients affected by …

Infection is a significant cause of morbidity and mortality in the malignant hematology
population. In comparison to solid tumors, hematologic malignancies are more likely to have …

Infections are a common complication in patients with many hematologic malignancies,
however, whether patients with myeloproliferative neoplasms (MPN) also are at an …

Simple Summary The Janus kinase-signal transducer and activator of transcription (JAK-
STAT) pathway is aberrantly activated in many malignancies. Inhibition of this pathway via …

Ruxolitinib is a Janus kinase (JAK) 1/2 inhibitor, currently used in the treatment of
myeloproliferative neoplasms. It exerts potent anti-inflammatory activity, but the involved …

Background Ruxolitinib is a selective Janus kinase inhibitor (JAKI) 1/2 approved for the
treatment of myelofibrosis (MF) and polycythemia vera (PV). These patients may be at risk …

Ruxolitinib improves disease-related constitutional symptoms, splenomegaly and overall
survival in myelofibrosis. However, studies suggest that the drug exerts immunosuppressive …

Aim Traditionally, early phase clinical trials in oncology have been performed in patients
based on safety risk-benefit assessment. Therapeutic transition to immuno-oncology may …

We herein report a 76-year-old Japanese man with myelofibrosis who developed
cryptococcal meningitis. After treatment for 5 months with ruxolitinib, the patient presented …

Ruxolitinib (RUX) is a kinase inhibitor used in the treatment of various medical conditions
and its mechanism of action involves suppression of the immune system. While beneficial in …